Literature DB >> 11557586

Inhibition of geranylgeranylation blocks agonist-induced actin reorganization in human airway smooth muscle cells.

R E Lesh1, C W Emala, H T Lee, D Zhu, R A Panettieri, C A Hirshman.   

Abstract

To determine whether RhoA isoprenylation (geranylgeranylation) is required for agonist-induced actin cytoskeleton reorganization (measured by an increase in the filamentous F- to monomeric G-actin ratio), human airway smooth muscle cells were treated for 72 h with inhibitors of geranylgeranyltransferase I. Geranylgeranyltransferase inhibitor (GGTI)-2147 or -286 pretreatment completely blocked the increase in the F- to G-actin fluorescence ratio when cells were stimulated with lysophosphatidic acid (LPA), endothelin, or carbachol. In contrast, LPA or endothelin induced actin cytoskeletal reorganization in cells treated with farnesyltransferase inhibitor (FTI)-277 to inactivate Ras. Forskolin-induced adenylyl cyclase activity was inhibited by carbachol in GGTI-2147-pretreated cells, demonstrating that the effect of geranylgeranyltransferase I inhibition on stress fiber formation was not due to uncoupling of signaling between the heterotrimeric G(i) protein (the Ggamma subunit is isoprenylated) and distal effectors. These results demonstrate that selective GGTIs can inhibit agonist-induced actin reorganization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557586     DOI: 10.1152/ajplung.2001.281.4.L824

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  7 in total

1.  Lysophosphatidic acid signaling protects pulmonary vasculature from hypoxia-induced remodeling.

Authors:  Hsin-Yuan Cheng; Anping Dong; Manikandan Panchatcharam; Paul Mueller; Fanmuyi Yang; Zhenyu Li; Gordon Mills; Jerold Chun; Andrew J Morris; Susan S Smyth
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-10-20       Impact factor: 8.311

Review 2.  A novel role for RhoA GTPase in the regulation of airway smooth muscle contraction.

Authors:  Wenwu Zhang; Youliang Huang; Yidi Wu; Susan J Gunst
Journal:  Can J Physiol Pharmacol       Date:  2014-11-25       Impact factor: 2.273

3.  RalA is overactivated in medulloblastoma.

Authors:  Kevin F Ginn; Ben Fangman; Kaoru Terai; Amanda Wise; Daniel Ziazadeh; Kushal Shah; Robyn Gartrell; Brandon Ricke; Kyle Kimura; Sharad Mathur; Emma Borrego-Diaz; Faris Farassati
Journal:  J Neurooncol       Date:  2016-08-26       Impact factor: 4.130

4.  Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells.

Authors:  Eric A Collisson; Celina Kleer; Mei Wu; Abhijit De; Sanjiv S Gambhir; Sofia D Merajver; Michael S Kolodney
Journal:  Mol Cancer Ther       Date:  2003-10       Impact factor: 6.261

5.  Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis.

Authors:  Mozaffarul Islam; Smita Sharma; Bhavna Kumar; Theodoros N Teknos
Journal:  Oral Oncol       Date:  2013-05-04       Impact factor: 5.337

6.  Simvastatin inhibits TGFβ1-induced fibronectin in human airway fibroblasts.

Authors:  Dedmer Schaafsma; Karol D McNeill; Mark M Mutawe; Saeid Ghavami; Helmut Unruh; Eric Jacques; Michel Laviolette; Jamila Chakir; Andrew J Halayko
Journal:  Respir Res       Date:  2011-08-24

7.  In PC3 prostate cancer cells ephrin receptors crosstalk to β1-integrins to strengthen adhesion to collagen type I.

Authors:  Miao Yu; Jinghe Wang; Daniel J Muller; Jonne Helenius
Journal:  Sci Rep       Date:  2015-02-03       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.